Richard Schumacher was terminated as chairman and chief executive officer of Boston Biomedica of West Bridgewater, Mass., the company said in a release, citing personal financial reasons. Schumacher, who founded the company in 1986, will remain on the board of directors, the company said.
, a director, was named chairman, while Kevin Quinlan, president and COO, will continue to manage operations. The board will create a committee to seek a replacement for Schumacher and to oversee the transition. The company provides life sciences services including specimen preparation for genomics/proteomics testing.
Carol Reed was named vice president, medical affairs, for Genaissance Pharmaceuticals of New Haven, Conn. Reed previously was executive director, medical affairs. Previously, she was associate medical director in pulmonary medical research for Bayer.
Ansbert Gädicke, general partner of MPM Capital, was named chairman of the new Elixir Pharmaceuticals upon the completion of the Cambridge, Mass.-based company’s merger with Centagenetix last week. Carl Weissman, also of MPM, joined the board. Edward Cannon will head serve as president and chief executive officer. Bard Geesaman, former VP of informatics for Centagenetix, was named vice president, medical.